Xembify (Immune Globulin Subcutaneous, Human-Klhw) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Xembify. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alirocumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anthrax immune globulin human.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asfotase alfa.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.
Xembify (Immune Globulin Subcutaneous, Human-Klhw) has 162 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Xembify (Immune Globulin Subcutaneous, Human-Klhw) has 0 major, 1 moderate, and 161 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Xembify. Always confirm against the full prescribing information.